Clinical trials: Nonalcoholic Fatty Liver
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
This is a study of experimental medication BMS-986036 given to healthy participants.
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03445208
- Testing
- BMS-986036
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Non-Alcoholic Fatty Liver Disease, Insulin Resistance
Effects of Carnitine Supplementation on Liver and Muscle
It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver.
- Trial name
- ECLIPSE (NCT03439917)
- Testing
- L-Carnitine tartrate, Meal Replacement Drink, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
Non-Alcoholic Fatty Liver Disease
Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and…
- Trial name
- NCT01262326
- Testing
- Calorie and Carbohydrate Restriction
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as…
- Trial name
- NCT06564584
- Testing
- TLC-2716 Dose 1, TLC-2716 Dose 2
- Where
- 4 sites in Mexico
- Volunteers
- 30 people
- Sponsor
- OrsoBio, Inc
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
Non Alcoholic Fatty Liver Diseases (NAFLD)
Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
The incidence of Non alcoholic fatty liver disease (NAFLD) continues to increase, and prevalence estimates for NAFLD range from 17-33%, making it is the most common cause of chronic liver disease in North America.
- Trial name
- NASHCR20 (NCT01324414)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Fatty Liver Disease, Nonalcoholic
Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic steatohepatitis (or NASH) is known to be caused by deposition of fat in the liver and development of scarring. This condition occurs more frequently in overweight and obese persons.
- Trial name
- NCT00596934
- Testing
- metreleptin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Elif Oral
Non-Alcoholic Fatty Liver Disease, Obese
Fatty Liver in Obesity: Long-lifestyle Follow-up (FLiO)
Non-alcoholic fatty liver disease (NAFLD) is a condition of excessive hepatic lipid accumulation in subjects that consume less than 20g ethanol per day, without other known causes as drugs consumption or toxins exposure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obese, Overweight
- Trial name
- FLiO (NCT03183193)
- Testing
- Control diet, FLiO diet
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
NAFLD, Diet Habit
Exploring the Mechanism of Dietary Pattern Improving MAFLD
investigators plan to observe the changes of biochemical indicators, body composition, gut microbiota, metabolomics in patients at different periods through balanced diet and Low-carbohydrate diet, so as to determine the…
- Trial name
- NCT05960396
- Testing
- Diet intervention
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Alcoholic Fatty Liver Disease
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Trial name
- SHIELD (NCT06355310)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes, Liver Fat
- Trial name
- NCT05751720
- Testing
- GIP/GLP-1a
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- Dr Adnan Agha
HIV Mono Infection
Nonalcoholic Steatohepatitis in HIV Mono-infection: Exploring Non-invasive Methods for Diagnosis and the Therapeutic Role of Vitamin E
Effective combination antiretroviral therapy (cART) has resulted in a dramatic reduction in AIDS mortality. Over the last decade, the proportion of deaths caused by liver-related etiologies, including co-infection with hepatitis…
- Trial name
- NCT03988725
- Testing
- Vitamin E
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Obesity, Obesity, Abdominal
Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD
This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in…
- Conditions
- Obesity, Obesity, Abdominal, NAFLD
- Trial name
- BRAVO (NCT05647915)
- Testing
- Berberine plus lifestyle intervention
- Where
- China
- Volunteers
- 337 people
- Sponsor
- China National Center for Cardiovascular Diseases
Non-Alcoholic Fatty Liver Disease
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty…
- Trial name
- AVAIL (NCT04807868)
- Testing
- Standard of care liver biopsy, Fibroscan, Biospecimen Collection
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.
- Trial name
- NCT05474560
- Testing
- Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Non-Alcoholic Fatty Liver Disease
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Over the past 30 years, the prevalence of childhood obesity in the United States has tripled from 5% to 15%. Major consequences of obesity include insulin resistance, type- 2 diabetes, cardiovascular disease and nonalcoholic…
- Trial name
- NCT01285362
- Testing
- Fish Oil Supplementation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Fatty Liver, Intermittent Fasting
Intermittent Fasting for NAFLD in Adults
NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI<30kg/m2) is an increasingly recognized condition, sometimes described as "lean…
- Conditions
- Fatty Liver, Intermittent Fasting, Fatty Liver, Nonalcoholic, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04899102
- Testing
- Time-Restricted, Intermittent Fasting
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease
Impact Of Choline in Patients With NAFLD
The study will be assessing the impact of choline supplementation in Non-alcoholic fatty liver disease patients using ultrasonography to show change in liver echogenicity, various laboratory tests as liver function, lipid profile…
- Trial name
- NCT05200156
- Testing
- Phosphatidyl Choline
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Non-alcoholic Fatty Liver Disease
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
The purpose of this study is to compare the severity of NAFLD in diabetic patients to that in non-diabetic patients.
- Trial name
- NCT03060694
- Testing
- diabetes
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine